Keith A Webster

US Patent:

6893867, May 17, 2005

Filed:

Nov 28, 2000

Appl. No.:

09/723326

Inventors:

Keith A. Webster - Key Biscayne FL, US

International Classification:

C12N015/63

US Classification:

4353201

Abstract:

Expression vectors are disclosed that are comprised of (a) one or more silencer elements and conditionally inducible elements to form silencer-inducible regions and (b) promoters in operative linkage upstream of at least one expressed region. The expression vector thereby regulates expression of at least one downstream region by conditional silencing in which an expressed DNA region of a gene is transcribed to produce RNA transcripts, which may or may not be translated to produce polypeptides. Genetically engineered mammalian cells and non-human mammals can be made using such expression vectors through transfection and transgenesis techniques. Moreover, processes of making and using the aforementioned products are disclosed (e. g. , the expression vector may be used diagnostically, therapeutically, or prophylactically).

US Patent:

20040152650, Aug 5, 2004

Filed:

Jul 22, 2003

Appl. No.:

10/624880

Inventors:

Keith Webster - Key Biscayne FL, US

International Classification:

A61K048/00
C12N005/02

US Classification:

514/044000, 435/375000

Abstract:

Hypoxia-acidosis-associated cell death is mediated by BNIP3, a member of the Bcl-2 family of apoptosis-regulating proteins. Chronic hypoxia induced the expression and accumulation of BNIP3 mRNA and protein in cardiac myocytes but acidosis was required to activate the death pathway. Acidosis stabilized BNIP3 protein and increased the association with mitochondria. Cell death by hypoxia-acidosis was blocked by pretreatment with antisense BNIP3 oligonucleotides. The pathway included extensive DNA fragmentation and opening of the mitochondrial permeability transition pore but no apparent caspase activation. Overexpression of wild type BNIP3, but not a translocation-defective mutant activated cardiac myocyte death when the myocytes were acidotic or hypoxic.

US Patent:

20050266549, Dec 1, 2005

Filed:

Apr 29, 2005

Appl. No.:

11/118963

Inventors:

Keith Webster - Key Biscayne FL, US

International Classification:

C12P021/06
C12N015/09

US Classification:

435320100, 435455000

Abstract:

Expression vectors are disclosed that are comprised of (a) one or more silencer elements and conditionally inducible elements to form silencer-inducible regions and (b) promoters in operative linkage upstream of at least one expressed region. The expression vector thereby regulates expression of at least one downstream region by conditional silencing in which an expressed DNA region of a gene is transcribed to produce RNA transcripts, which may or may not be translated to produce polypeptides. Genetically engineered mammalian cells and non-human mammals can be made using such expression vectors through transfection and transgenic techniques. Moreover, processes of making and using the aforementioned products are disclosed (e.g., the expression vector may be used diagnostically, therapeutically, or prophylactically).

US Patent:

20130131152, May 23, 2013

Filed:

Nov 1, 2010

Appl. No.:

13/504438

Inventors:

Keith A. Webster - Key Biscayne FL, US

Assignee:

UNIVERSITY OF MIAMI - Miami FL

International Classification:

A61K 31/7088

US Classification:

514 44 R, 4353201

Abstract:

Methods and compositions for the treatment of hypoxia associated disorders by directional angiogenesis/arteriogenesis. Conditionally silenced vectors expressing a therapeutic molecule under hypoxic conditions avoid chaotic vascularization and allow for the orderly growth of new vessels into damaged tissue.

US Patent:

20130236433, Sep 12, 2013

Filed:

Nov 10, 2011

Appl. No.:

13/884057

Inventors:

Keith A. Webster - Key Biscayne FL, US

International Classification:

A61K 35/28
A61K 31/7088
A61K 35/12

US Classification:

424 937

Abstract:

The methods, compositions, cells and kits described herein are based on the discovery that stem cells, when injected into ischemic tissue of mammals, can be protected by preconditioning of the ischemic tissue with hypoxia-regulated human VEGF and human IGF-1. Methods, compositions, cells and kits for treating tissue injured by ischemia or at risk of ischemic injury in a subject are thus described herein.

US Patent:

20130302293, Nov 14, 2013

Filed:

Nov 11, 2011

Appl. No.:

13/884054

Inventors:

Keith A. Webster - Key Biscayne FL, US

International Classification:

C12N 15/85
A61K 35/28
C12N 15/86

US Classification:

424 9321, 435325, 435366

Abstract:

Described herein are compositions, kits and methods for stimulating angiogenic functions of stem cells and/or progenitor cells having pro-angiogenic potential (e.g., endothelial progenitor cells (EPCs), mesenchymal stem cells (MSCs)) before transplantation (e.g., ex vivo cell therapy) based on the discovery that functional recovery of CD34+ cells from coronary artery disease (CAD) patients is improved by transfection of antagomirs against one or more miRs of a plurality of miRs identified to be over-expressed in cells from CAD patients. Described herein are methods to recover the functions of EPCs isolated from patients with cardiovascular disease (e.g., CAD or peripheral artery disease (PAD)) by bioengineering the cells with antagomirs and/or premirs to specific micro-RNAs. The bioengineered cells can then be used to treat patients with ischemic or ischemic-related disease (e.g., CAD or PAD) by autologous stem cell therapy.

US Patent:

20150322410, Nov 12, 2015

Filed:

Jul 15, 2015

Appl. No.:

14/800041

Inventors:

- Miami FL, US
KEITH A. WEBSTER - Key Biscayne FL, US

International Classification:

C12N 7/00
C12N 15/86
C07K 14/515

Abstract:

Methods and compositions for the treatment of hypoxia associated disorders by directional angiogenesis/arteriogenesis. Conditionally silenced vectors expressing a therapeutic molecule under hypoxic conditions avoid chaotic vascularization and allow for the orderly growth of new vessels into damaged tissue.

US Patent:

20150139952, May 21, 2015

Filed:

Aug 11, 2014

Appl. No.:

14/456084

Inventors:

- Miami FL, US
Keith A. Webster - Key Biscayne FL, US

International Classification:

A61K 38/30
A61K 38/18
A61K 48/00
A61K 35/28

US Classification:

424 932, 424 937

Abstract:

The methods, compositions, cells and kits described herein are based on the discovery that stem cells, when injected into ischemic tissue of mammals, can be protected by preconditioning of the ischemic tissue with hypoxia-regulated human VEGF and human IGF-1. Methods, compositions, cells and kits for treating tissue injured by ischemia or at risk of ischemic injury in a subject are thus described herein.

Address:

740 Allendale Rd, Key Biscayne, FL 33149

Phone:

3053617805

VIN:

1FAFP34N37W289093

Make:

FORD

Model:

FOCUS

Year:

2007